Ancitabine

Ancitabine non-toxically inhibits vaccinia virus replication in BSC40 African green monkey kidney cells with a 48 h IC₉₉ of 11 μM, acting by blocking viral DNA replication and preventing progression from early to late viral protein synthesis^[1].
Ancitabine (5 μg/mL; 2 days) completely inhibits replication of the KOS strain of HSV-1 in HEL cells^[2].
Ancitabine (5 μg/mL; 2 days) completely inhibits replication of the Savage strain of HSV-2 in HEL cells^[2].
Ancitabine (0.14-10 μg/mL; 4 days) potently inhibits replication of the AD169 strain of HCMV in HEL cells, with an ED₉₀ of 0.14 μg/mL and complete inhibition at 10 μg/mL maintained for 4 days^[2].
Ancitabine (<0.010->100 μg/mL; 4 days) is non-toxic to stationary HEL cells at concentrations up to 100 μg/mL, but is highly cytotoxic to growing HEL cells with a CyD₅₀ of <0.010 μg/mL^[2].
Ancitabine (500 μM; 48 h) is converted to its triphosphate form in HCMV-infected HEL cells^[2].
Ancitabine (5 μg/mL; 48 h) substantially suppresses synthesis of HCMV DNA in infected HEL cells^[2].
Ancitabine (10 μM; 72 h) induces intracellular vesicle formation in human colorectal carcinoma HCT116 cells with reproducible morphological profiles^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.